Non steroidal aromatase inhibitors

Class of drugs used in the treatment of estrogen-dependent conditions

Non-steroidal aromatase inhibitors (NSAIs) are a class of drugs that inhibit the enzyme aromatase, which is responsible for the conversion of androgens into estrogens. These inhibitors are primarily used in the treatment of estrogen receptor-positive breast cancer in postmenopausal women. Unlike steroidal aromatase inhibitors, NSAIs do not have a steroidal structure and are often preferred due to their specificity and fewer side effects.

Mechanism of Action

Metabolic pathways of estrogen production

NSAIs work by binding to the aromatase enzyme, thereby preventing it from converting androgens such as testosterone and androstenedione into estrogens. This reduction in estrogen levels is beneficial in treating estrogen-dependent cancers, as it deprives the cancer cells of the estrogen they require for growth and proliferation.

Common Non-Steroidal Aromatase Inhibitors

A general letrozole pharmacophore model

The most commonly used NSAIs include:

• Anastrozole - Marketed under the brand name Arimidex, anastrozole is a potent inhibitor of aromatase and is used as a first-line treatment for hormone receptor-positive breast cancer.
• Letrozole - Sold under the brand name Femara, letrozole is another widely used NSAI that is effective in reducing estrogen levels and is often used in the adjuvant treatment of breast cancer.
• Exemestane - Although structurally different, exemestane is sometimes grouped with NSAIs due to its similar mechanism of action.

Clinical Applications

NSAIs are primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. They are often prescribed after surgery to reduce the risk of cancer recurrence. In some cases, they are used as a neoadjuvant therapy to shrink tumors before surgery.

Side Effects

Common side effects of NSAIs include hot flashes, joint pain, and fatigue. Long-term use can lead to decreased bone mineral density, increasing the risk of osteoporosis and fractures. Patients are often monitored for these side effects, and additional treatments may be prescribed to mitigate them.

Synthesis and Development

Synthesis of letrozole

The development of NSAIs involved the identification of compounds that could selectively inhibit the aromatase enzyme without affecting other steroidogenic pathways. The synthesis of letrozole, for example, involves the creation of a triazole ring, which is crucial for its inhibitory activity.

Comparison with Steroidal Aromatase Inhibitors

Classification of aromatase inhibitors

Steroidal aromatase inhibitors, such as formestane and exemestane, mimic the structure of natural substrates and bind irreversibly to the aromatase enzyme. In contrast, NSAIs bind reversibly and are often preferred due to their lower risk of cross-reactivity with other steroidogenic enzymes.

Related Pages

• Aromatase
• Breast cancer treatment
• Hormone therapy (oncology)
• Estrogen receptor